Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Change in Receivables (2016 - 2025)

Utah Medical Products (UTMD) has 16 years of Change in Receivables data on record, last reported at $506000.0 in Q3 2025.

  • For Q3 2025, Change in Receivables rose 5522.22% year-over-year to $506000.0; the TTM value through Sep 2025 reached $626000.0, up 270.41%, while the annual FY2024 figure was $835000.0, 136.78% up from the prior year.
  • Change in Receivables reached $506000.0 in Q3 2025 per UTMD's latest filing, up from -$397000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $1.2 million in Q3 2022 and bottomed at -$1.8 million in Q1 2023.
  • Average Change in Receivables over 5 years is -$67473.7, with a median of $9000.0 recorded in 2024.
  • The widest YoY moves for Change in Receivables: up 5522.22% in 2025, down 578.31% in 2025.
  • A 5-year view of Change in Receivables shows it stood at -$760000.0 in 2021, then crashed by 37.5% to -$1.0 million in 2022, then surged by 86.89% to -$137000.0 in 2023, then surged by 486.13% to $529000.0 in 2024, then dropped by 4.35% to $506000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $506000.0 in Q3 2025, -$397000.0 in Q2 2025, and -$12000.0 in Q1 2025.